Fig. 1From: Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort studySchematic of study design. UMEC/VI, umeclidinium/vilanterol; TIO, tiotropiumBack to article page